102 related articles for article (PubMed ID: 17088999)
1. MEK ablation in MCF-7 cells blocks DNA synthesis induced by serum, but not by estradiol or growth factors.
Estes NR; Thottassery JV; Westbrook L; Kern FG
Int J Oncol; 2006 Dec; 29(6):1573-80. PubMed ID: 17088999
[TBL] [Abstract][Full Text] [Related]
2. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
3. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
5. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
7. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
8. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
9. Growth factor-specific regulation of insulin receptor substrate-1 expression in MCF-7 breast carcinoma cells: effects on the insulin-like growth factor signaling pathway.
Lassarre C; Ricort JM
Endocrinology; 2003 Nov; 144(11):4811-9. PubMed ID: 12960057
[TBL] [Abstract][Full Text] [Related]
10. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
11. siRNA mediated knockdown of fibroblast growth factor receptors 1 or 3 inhibits FGF-induced anchorage-independent clonogenicity but does not affect MAPK activation.
Estes NR; Thottassery JV; Kern FG
Oncol Rep; 2006 Jun; 15(6):1407-16. PubMed ID: 16685373
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling.
Varma H; Conrad SE
Cancer Res; 2002 Jul; 62(14):3985-91. PubMed ID: 12124331
[TBL] [Abstract][Full Text] [Related]
13. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
Yan Y; Spieker RS; Kim M; Stoeger SM; Cowan KH
Oncogene; 2005 May; 24(20):3285-96. PubMed ID: 15735702
[TBL] [Abstract][Full Text] [Related]
14. Growth factor-induced transcription via the serum response element is inhibited by cyclic adenosine 3',5'-monophosphate in MCF-7 breast cancer cells.
Lowe WL; Fu R; Banko M
Endocrinology; 1997 Jun; 138(6):2219-26. PubMed ID: 9165004
[TBL] [Abstract][Full Text] [Related]
15. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.
Oh AS; Lorant LA; Holloway JN; Miller DL; Kern FG; El-Ashry D
Mol Endocrinol; 2001 Aug; 15(8):1344-59. PubMed ID: 11463858
[TBL] [Abstract][Full Text] [Related]
16. ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.
Sharma-Walia N; Krishnan HH; Naranatt PP; Zeng L; Smith MS; Chandran B
J Virol; 2005 Aug; 79(16):10308-29. PubMed ID: 16051824
[TBL] [Abstract][Full Text] [Related]
17. The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1.
Khanal P; Namgoong GM; Kang BS; Woo ER; Choi HS
Mol Cancer Ther; 2010 Mar; 9(3):606-16. PubMed ID: 20179161
[TBL] [Abstract][Full Text] [Related]
18. Suppression of coronavirus replication by inhibition of the MEK signaling pathway.
Cai Y; Liu Y; Zhang X
J Virol; 2007 Jan; 81(2):446-56. PubMed ID: 17079328
[TBL] [Abstract][Full Text] [Related]
19. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
20. MAP kinase: it's been longer than fifteen minutes.
Sturgill TW
Biochem Biophys Res Commun; 2008 Jun; 371(1):1-4. PubMed ID: 18406346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
